🌅 Today's Morning Call
|
S&P Futures
7,653.75
▼ -42.75 (-0.56%)
|
Nasdaq Futures
29,177.25
▼ -305.50 (-1.04%)
|
Dow Futures
52,931.00
▼ -331.00 (-0.62%)
|
|
10Y Treasury
4.76%
▲ +0.04%
|
US Dollar
99.61
▲ +0.10 (+0.10%)
|
Bitcoin
$78,037
▼ -$526 (-0.67%)
|
Data as of 8:07 AM ET
Good morning! Happy Tuesday. Markets are waking up in a cautious mood after two Saudi oil tankers were hit in the Strait of Hormuz overnight, and futures are pointing lower across the board. Pharma is the sector to watch, with Novartis, AstraZeneca, and GSK all dropping headlines. Here's your morning rundown.
👀 What to Watch Today
The big overnight story is geopolitical: two supertankers carrying Saudi crude were struck by unknown projectiles while sailing out of the Strait of Hormuz. Roughly a fifth of the world's oil flows through that chokepoint, so keep energy names and crude prices at the top of your radar today.Healthcare is your other main event. Novartis (NVS) is fighting a two-front battle after strong MS drug data collided with paused cell therapy trials, while AstraZeneca (AZN) and GSK posted encouraging late-stage results of their own.
With the 10-year yield ticking up to 4.76% and the dollar firming, watch how rate-sensitive tech handles the pressure. Nasdaq futures are the weakest of the majors this morning at -1.04%.
Your Phone Is Smarter Than Your Inbox
Not every market move can wait. Our text alerts deliver the ones that can't. One short alert, straight to your phone, when something is worth seeing now. No fluff. No noise. No charge.
Text Me the Alerts🌏 Overnight Recap
The Hormuz tanker attacks dominated overnight tape, sending a jolt through energy markets and pushing traders toward safety. Watch for crude to open sharply as shipping intelligence firms scramble to assess the damage and any disruption to Saudi outbound flows.Treasury yields nudged higher across the curve, with the 10-year at 4.76%, the 30-year at 5.25%, and the 5-year at 4.51%. The dollar index climbed to 99.61, a classic risk-off tilt as investors reprice geopolitical uncertainty.
Bitcoin slipped 0.67% to around $78,037, showing little of its usual safe-haven appeal on a jittery morning. The setup points to a defensive open, with energy the likely standout and growth names on the back foot.
Sponsored Content
The $15 Gold Fund That Pays Up to $1,152/Month
A $15 fund is quietly paying regular investors up to $1,152 a month from gold's rally. Not mining stocks. Not options. Not a single ounce of physical metal. Something most investors have never heard of.
The next payout is just days away. If you're not positioned before it hits, you're watching income walk out the door.
📊 Pre-Market Movers
Novartis (NVS) is the morning's headline conflict. Its oral MS drug remibrutinib beat a rival in two late-stage studies, but that win is offset by news it paused eight clinical trials of an autoimmune cell therapy after three patient deaths. Expect a tug-of-war on the tape.AstraZeneca (AZN) could catch a bid after its Tagrisso and Orpathys lung cancer combo significantly improved progression-free survival in a Chinese late-stage trial. GSK (GSK) is also in focus after advancing its mRNA flu vaccine to late-stage testing on strong immune response data.
Medtronic (MDT) raised its full-year outlook on higher profit and sales, backed by over $700 million in heart tech and robotics spending. Ford (F) faces headline risk from its recall of nearly 149,000 vehicles.
🔍 Today's Watchlist
- Crude oil and energy names as the Hormuz tanker attack disrupts a key shipping corridor.
- Novartis (NVS) navigating both positive MS drug data and paused cell therapy trials after patient deaths.
- Healthcare sector broadly with AZN, GSK, and MDT all making pipeline and outlook news.
- The 10-year Treasury yield at 4.76% and a firmer dollar pressuring rate-sensitive tech.
- Ford (F) after its 149,000-vehicle U.S. recall over power loss and visibility issues.
Sponsored Content
Huge AI Announcement Coming on September 3
The last time this firm did this, it skyrocketed overnight. Now – backed by a $51 billion backlog, a SpaceX partnership, and President Trump’s ringing endorsement – the gains could be even bigger.
🎯 The Morning Playbook
The play today is defense with a geopolitical lean. The Hormuz tanker strikes hand energy names a catalyst, so watch crude and oil producers for outperformance while broader risk assets stay soft. A firmer dollar and higher yields argue for patience on high-multiple tech.Healthcare offers stock-specific opportunity. Winners like AZN, GSK, and MDT are separating from the pack, while NVS forces you to weigh a clear positive against a real safety setback. Read the details before reacting.
Cautious positioning beats chasing today. Let the open settle, watch how crude and yields behave, and keep your watchlist tight. Discipline pays on days that start defensive.
📰 Further Reading
This tiny piece of glass could be bigger than GPUs (Ad)
It's smaller than a fingertip. It's made of glass. And it's about to reshape AI from the ground up. Jensen Huang, Nvidia's CEO, says this device is shattering the limitations of AI and without it, AI can't scale. Google Ventures says it's the future of AI compute. And Sequoia Capital – the firm that...
Click here to learn more. (No purchase necessary.)
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (Ad)
A small Colorado company now owns rights to a tech that could save the entire public power grid from collapse. And billionaire Sam Altman is now an investor.
Click here to learn this company's name for free.
Every Rocket Has This Problem (Ad)
This equation is why rockets are mostly fuel and why launching anything to space costs a fortune: Δv = vₑ ln(m₀/m_f) SpaceX hasn't solved it. Neither has Blue Origin. Neither has Rocket Lab. But one tiny company operating next door to SpaceX did. Robert Kiyosaki's "Financial 007" says early investor...
Click Here to See How They Solved It